key: cord-0765332-ckxnoo26 authors: Attauabi, Mohamed; Dahlerup, Jens Frederik; Poulsen, Anja; Hansen, Malte Rosager; Vester-Andersen, Marianne Kajbæk; Eraslan, Sule; Prahm, August Pilegaard; Pedersen, Natalia; Larsen, Lone; Jess, Tine; Neumann, Anders; Haderslev, Kent V; Molazahi, Akbar; Lødrup, Anders Berg; Glerup, Henning; Oppfeldt, Asser Mathiassen; Jensen, Michael Dam; Theede, Klaus; Kiszka-Kanowitz, Marianne; Seidelin, Jakob Benedict; Burisch, Johan title: Outcomes and Long-Term Effects of COVID-19 in Patients with Inflammatory Bowel Diseases – A Danish Prospective Population-Based Cohort Study with Individual-Level Data date: 2021-11-10 journal: J Crohns Colitis DOI: 10.1093/ecco-jcc/jjab192 sha: 6b28a6bc0b28a2298fb6d45a8cec160b5513fef7 doc_id: 765332 cord_uid: ckxnoo26 BACKGROUND AND AIMS: The health consequences of coronavirus disease 2019 [COVID-19] among patients with ulcerative colitis [UC] and Crohn’s disease [CD] remain largely unknown. We aimed to investigate the outcomes and long-term effects of COVID-19 in patients with UC or CD. METHODS: We conducted a prospective, population-based study covering all Danish patients with CD or UC and confirmed COVID-19 between January 28, 2020 and April 1, 2021, through medical records and questionnaires. RESULTS: All 319 patients with UC and 197 patients with CD who developed COVID-19 in Denmark were included in this study and compared with the Danish background population with COVID-19 [N = 230 087]. A significantly higher risk of COVID-19-related hospitalization was observed among patients with UC (N = 46 [14.4%], relative risk [RR] = 2.49 [95% confidence interval, CI, 1.91–3.26]) and CD (N = 24 [12.2%], RR = 2.11 [95% CI 1.45–3.07]) as compared with the background population (N = 13 306 [5.8%]). A similar pattern was observed for admission to intensive care (UC: N = 8 [2.51%], RR = 27.88 [95% CI 13.88–56.00]; CD: N = 3 [1.52%], RR = 16.92 [95% CI 5.46–52.46]). After a median of 5.1 months (interquartile range [IQR] 4.5–7.9), 58 [42.3%] and 39 [45.9%] patients with UC and CD, respectively, reported persisting symptoms which were independently associated with discontinuation of immunosuppressive therapies during COVID-19 (odds ratio [OR] = 1.50 [95% CI 1.07–10.22], p = 0.01) and severe COVID-19 (OR = 2.76 [95% CI 1.05–3.90], p = 0.04), but not with age or presence of comorbidities. CONCLUSION: In this population-based study of 516 patients with IBD and COVID-19, 13.6% needed hospitalization and 2.1% required intensive care. Furthermore, sequelae were frequent, affecting 43.7% of COVID-19-infected patients. These findings might have implications for planning the healthcare of patients in the post-COVID-19 era. Coronavirus disease 2019 , caused by the coronavirus SARS-CoV-2 and first reported in December 2019, is a new form of acute infectious respiratory syndrome, with a broad spectrum of multi-organ manifestations and severities. 1 The disease has become a pandemic, with over 177 million affected cases and 3.8 million deaths as of June 2021, resulting in global healthcare crises and strained healthcare resources. 2 As the vast majority of patients survive COVID-19, it is therefore paramount to investigate the possible long-term effects of COVID-19. To date, only two hospital-based cohort studies are available. 3, 4 Together, their data indicate a high risk of clinical sequelae following COVID-19, which also seem to be evident among younger and middle-aged patients with no comorbidities. 3, 4 Inflammatory bowel diseases [IBD] , consisting of ulcerative colitis [UC] and Crohn's disease [CD] , are chronic, immune-mediated inflammatory diseases with an increasing incidence. 5 Although patients frequently require immunosuppressive therapies, which have been shown to increase the risk of some infections, 6 the susceptibility to SARS-CoV-2 infection seems not to differ among patients with and without IBD, regardless of IBD-related medications. [7] [8] [9] However, only three population-based studies have assessed the outcomes of COVID-19 among patients with IBD, 7, 10, 11 and data on the influence of IBD medication on COVID-19 outcomes are conflicting. 7, 8, [12] [13] [14] Furthermore, population-based estimates of the long-term effects of COVID-19 in IBD patients are lacking. In this study, we aimed to investigate the severity, outcomes and long-term health effects of COVID-19 in a Danish generalizable population-based cohort of patients with IBD. The Danish COVID-IBD cohort is a prospectively maintained population-based cohort. 7 Briefly, the cohort was established among all internal medicine and gastrointestinal departments in Denmark at the beginning of April 2020 and prospectively included all patients with an established diagnosis of IBD according to current diagnostic criteria 15, 16 who developed COVID-19. The inclusion period was from the first test for SARS-CoV-2 in Denmark, which took place on January 28, 2020, until April 1, 2021. In Denmark, all residents could book an appointment for PCR [polymerase chain reaction] testing beginning May 18, 2020 without a prescription; before that, a PCR test required a physician's referral. All healthcare is free and universal in Denmark. Four out of five geographically well-defined regions covering 4.43 million residents [equal to 78.6% of the Danish population], and each responsible for maintaining all healthcare within their respective geographical areas, delivered complete population-based data on individual patients for this study. The data included test results from reverse transcription PCR [RT-PCR] analysis for the presence of SARS-CoV-2. These data were linked to IBD-related and COVID-19-related clinical data from the patients' unique medical records and their answers to validated questionnaires, as described below. The fifth region, the Region of Southern Denmark, with 1.2 million residents, was covered by including all relevant hospital departments and performing a manual assessment of their outpatient lists. For the assessment of COVID-19 outcomes within the background population, data were provided by all five regions; however, these data were limited to the outcomes of COVID-19 and the patients' ages. The primary outcomes of this study were the severity of COVID-19 and development of any long-term effects following it, including their characterization and associated factors. Secondary outcomes included health-related quality of life, clinical relapse of IBD and re-infection with COVID-19 during follow-up. The clinical diagnosis of COVID-19 relied on a positive nucleic acid amplification test [RT-PCR] for SARS-CoV-2, 17 18 This outcome was primarily patient-reported through secure surveys, which were sent to the whole population irrespective of hospital contact. Survey answers were subsequently verified by physicians when possible. Similarly, patient-reported health-related quality of life was measured prospectively after COVID-19, using the EuroQol fivedimension five-level [EQ-5D-5L] questionnaire, 19 Recent guidelines suggest the following criteria for COVID-19 re-infection, which were adapted in this study: 24 [i] confirmation of a first episode of COVID-19, [ii] proof of a re-infection with two positive SARS-CoV-2 RT-PCR tests, and [iii] at least one, and ideally two, negative RT-PCR tests, on two different specimens collected between the first and second episodes. A less stringent approach, presented in the same guidelines, 24 was adopted in this study for a separate analysis and includes the clinical recurrence of symptoms compatible with COVID-19 accompanied by a positive PCR test for SARS-CoV-2 more than 90 days after the onset of the primary infection and with no evidence of another cause of infection. Descriptive statistics were used to measure prevalences and incidences. Differences between UC and CD were investigated using the chi-squared test and Fisher's exact test, as appropriate. In addition, binary logistic regression models were used to investigate possible categorical variables as predictive factors for the disease course of COVID-19 and IBD. The primary predictor variables, which were determined a priori, included IBD medications with an emphasis on immunosuppressive therapies and 5-aminosalicylic acid , IBD activity, and severity of COVID-19. In addition, covariates were determined by backward selection to obtain statistically relevant variables for bivariate analysis. We considered age, gender, comorbidities, and IBD localization and behaviour according to the Montreal classification. Outcomes including associated factors were analysed separately for UC and CD. If an analysis could not be conducted due to a limited sample size, data on CD and UC patients were pooled, and adjusted analysis was conducted; p-values <0.05 were considered to be significant for all analyses. Statistical analyses, including data preparation, were performed using R version 3.6.1, developed by the R Foundation for Statistical Computing. All data are incorporated within the article and its online Supplementary Data. No patients were involved in setting the research question or the outcome measures, planning the study design or interpretation, or in writing up the results. During the inclusion period, a total of 516 patients with IBD and 230 087 patients without IBD developed COVID-19, and all were included in this study. The baseline demographic and clinical characteristics were available on patients with IBD and are reported in Table 1 and in Supplementary Data p. 5. The cohorts of UC and CD were comparable in terms of age and gender but not in terms of the proportion of patients in remission or patients receiving or not receiving IBD-related medications. All patients who received systemic steroids did so due to IBD-related disease activity. The outcomes of COVID-19 are depicted in Figure 1 Figure 1 ]; however, as shown, very few patients with IBD were available for the analysis of these outcomes. The sub-analysis of outcomes of COVID-19 in relation to age showed that these outcomes merely appeared in elderly patients, which was particularly evident among IBD patients [Supplementary Data pp. [5] [6] . In patients with UC, adverse COVID-19 was independently associated with being older than 50 years (odds ratio [ IBD-related medications were not associated with the disease course of COVID-19 in patients with either UC or CD [Supplementary Data pp. 7-10]. However, when including 5-ASA into an adjusted and pooled analysis of UC and CD, this medication was associated with an increased risk of COVID-19-related mortality compared with patients who did not receive 5-ASA and those who did not receive any IBD medications [Supplementary Data p. 11]. However, the patients were all high-risk individuals and are described individually in detail [Supplementary Data p. 12]. The median time to assess long-term outcomes of COVID-19 was 5.1 months (interquartile range [IQR] 4.5-7.9] after infection. The health-related quality of life after COVID- 19 Following COVID- 19 Before vaccination of the cohort began on December 27, 2020, the diagnosis of COVID- 19 COVID-19 pneumonia. This patient's first COVID-19 infection was also adverse and required hospitalization. The burden of COVID-19, including the number of affected individuals, constitutes an unprecedented health challenge. To manage these patients, data from extensive population-based studies are urgently needed to ensure informed decision-making based on generalizable conclusions in the planning and prioritization of healthcare. To our knowledge, this is the first population-based study with data at the level of individual patients to assess the short-and long-term health consequences of COVID-19 and the first study to address the long-term effects of COVID-19 in patients with UC and CD. Within our cohort, we demonstrate a relatively high risk of adverse and severe COVID-19 among patients with IBD. Second, we found that approximately 40% of patients with UC and CD experienced persisting symptoms of COVID-19 during follow-up after a median of 5 months, which was associated with discontinuation of immunosuppressive therapies for UC due to COVID-19 and adverse COVID-19 among patients with CD. Assessing the disease activity of IBD following COVID-19, we found that relapse of CD was independently associated with adverse COVID-19, the L4 phenotype, and use of ustekinumab and infliximab during COVID-19 infection. To our knowledge, only one study has conducted a direct comparison of outcomes of COVID-19 among patients with IBD and the background population. 11 As with that study, we found a high risk of adverse COVID-19 among patients with UC and CD as compared with the background population. We also found a high risk of severe COVID-19, something that was not detected in the Swedish study. An important distinction between our study and the report from Sweden is that the latter included all patients with IBD as a reference; in contrast, we only included those with confirmed COVID-19. Furthermore, the Swedish report could not distinguish between UC and CD or assess the results in relation to IBD disease activity or medications. Nonetheless, our analyses should also be interpreted with caution as the analysis was based on very few patients and therefore needs to be confirmed in larger population-based generalizable cohorts. In our cohort, a large proportion of patients with UC and CD reported sequelae after a median of 5 months, which most frequently included fatigue, anosmia and ageusia. This is consistent with findings from another large, ambidirectional cohort study with 6 months of follow-up of non-IBD patients discharged from hospitals in China. 3 As in that study, we found no association between clinical sequelae and age or the presence of comorbidities, which is clinically relevant as it indicates that sequelae following COVID-19 are to be expected not only among elderly patients with comorbidities. However, emerging data suggest that sequelae might become more prevalent with increasing age and comorbidities. 4 Our study also found that discontinuation of immunosuppressive therapies during COVID-19 was independently associated with the development of clinical sequelae following COVID-19 among patients with UC. As far as we know, this topic has not yet been investigated among patients with IBD or other immune-mediated inflammatory diseases and, therefore, might have implications for the management and awareness of this group of patients in the post-COVID-19 era. The finding that short-term clinical relapse of CD was independently associated with the severity of COVID-19 is intriguing, but should be interpreted with caution until it has been verified in other cohorts, in light of the limited sample size in ours. 26, 27 The initial concern about treatment with immunosuppressive therapies during the COVID-19 pandemic was related to the balance between the risk of deterioration of COVID-19 and the risk of clinical relapse of UC and CD. 7 Reassuringly, we found no association between discontinuation of immunosuppressive therapies during COVID-19 and clinical relapse of IBD, and no association between use of these medications and the severity of COVID-19. However, data regarding the latter are conflicting. 7, 12, 13, [28] [29] [30] Of particular interest is the consistent finding that 5-ASA is independently associated with severe COVID-19. 13, 28, 29 However, this finding was not verified in the most recent update from the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease [SECURE-IBD] registry. 14 In the current study, we did find 5-ASA to be associated with COVID-19-related mortality in an adjusted analysis; however, all patients who died of COVID-19 while receiving 5-ASA were already high-risk individuals, and a similar pattern can be recognized in the most recent description of the SECURE-IBD registry. 14 The unclear causal relationship between 5-ASA and COVID-19-related outcomes is further complicated by different control groups, study designs and treatment guidelines for the use of 5-ASA across countries. To our knowledge, the current study provides the first evidence for the development of clinical sequelae in a population-based setting that focuses on patients with UC and CD. The strengths of this study include its population-based design with individual-level data for the whole spectrum of patients with a confirmed diagnosis of IBD and COVID-19. Linking population-based data with patients' unique medical records and their responses to validated questionnaires provides novel insights into the clinical course during, and sequelae following, COVID-19, including assessment of associated factors in a real-life setting in one of the largest cohorts to date. This was further reinforced by standardized case ascertainment methods within our relatively homogeneous population treated according to uniform national guidelines. However, we acknowledge several limitations to our study, the first being its observational study design, which hindered a systematic approach, such as using systematic pulmonary CT scans, as reported in a study of non-IBD patients. 3 Second, the clinical sequelae following COVID-19, which were investigated among less than every second patient, were not limited to physician-verified outcomes and were limited by sample size and wide confidence intervals. Finally, this study was not designed to investigate specific variants of SARS-CoV-2 or the disease activity of IBD following COVID-19 in comparison with a non-COVID-19 population. These limitations warrant further investigation. In conclusion, we have found that in this prospective, population-based cohort of unselected patients with either UC or CD who developed COVID-19, the outcomes appeared to be more unfavourable among these patients than among the background population, albeit with small sample sizes in the subanalyses, and that patients with IBD were prone to develop clinical and psychological sequelae. This study identifies clinical factors that might help guide physicians in decision-making and could have implications in the healthcare planning for post-COVID-19 sequelae in patients with IBD. None. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of Coronavirus Disease 2019 in China COVID-19) Dashboard. World Health Organization 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. Epub ahead of print 2021 Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies Relevant infections in inflammatory bowel disease, and their relationship with immunosuppressive therapy and their effects on disease mortality Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease-a Danish prospective population-based cohort study Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies -a Danish population-based cohort study Are patients with inflammatory bowel disease at an increased risk of developing SARS-CoV-2 than patients without inflammatory bowel disease? Results from a nationwide veterans' affairs cohort study Clinical outcomes of Covid-19 in patients with inflammatory bowel disease: a nationwide cohort study Inflammatory bowel disease and risk of severe COVID-19: a nationwide population-based cohort study in Sweden Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology? Effect of IBD medications on COVID-19 outcomes: results from an international registry 5-Aminosalicylates are not associated with adverse outcomes in inflammatory bowel disease patients with COVID-19: analysis from an international registry Ulcerative colitis. An epidemiological study based on a regional inception cohort, with special reference to disease course and prognosis Crohn's disease-occurrence, course and prognosis. An epidemiologic cohort-study WHO COVID-19: Case Definitions. World Health Organization Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) EQ-5D: a measure of health status from the EuroQol Group The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut. Epub ahead of print Development and psychometric testing of inflammatory bowel disease fatigue (IBD-F) patient self-assessment scale Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. Epub ahead of print Faecal calprotectin indicates intestinal inflammation in COVID-19 Letter: SARS-CoV-2-induced gastrointestinal inflammation but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an International Registry Letter: Risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study The authors are grateful to all Danish COVID-IBD Study Group members who have screened the outpatient lists for COVID-19. The group members are listed in the Supplementary Data, p. 2. Supplementary data are available at ECCO-JCC online.